Hi@Everyone This meta-analysis aimed to evaluate the efficacy of methylene blue in patients with distributive shock, following PRISMA guidelines and examining randomized controlled trials from PubMed, Embase, and the Cochrane Library until April 19, 2023. The study, which included six RCTs with a total of 265 participants, found no significant difference in mortality rates between the methylene blue and placebo groups. However, methylene blue was associated with reduced durations of mechanical ventilation, ICU length of stay, and hospital length of stay. These findings suggest that while methylene blue does not significantly impact mortality in distributive shock patients, it may contribute to shorter mechanical ventilation periods and hospital stays, indicating the need for further clinical research in this area.
top of page
Infectious Disease & Sepsis
Public·454 members
About
Welcome to the group! Connect with other members, get updates and share media.
bottom of page